Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DB8G4D
|
|||
| Drug Name |
JSP191
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Hematopoietic stem cell transplantation [ICD-11: QB63; ICD-10: Z00-Z99] | Phase 1/2 | [1] | |
| Company |
Jasper Therapeutics
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05357482) Addition of JSP191 (C-kit Antibody) to Non-myeloablative Hematopoietic Cell Transplantation For Sickle Cell Disease and Beta-Thalassemia. U.S.National Institutes of Health. | |||
| REF 2 | Physiologically-based pharmacokinetic modeling of immunoglobulin and antibody coadministration in patients with primary human immunodeficiency. CPT Pharmacometrics Syst Pharmacol. 2022 Oct;11(10):1316-1327. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.